Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value
On Thursday, Novavax Inc NVAX reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sales under APA agreements.
Novavax (NVAX) Reports Q4 Loss, Tops Revenue Estimates
Novavax (NVAX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $1.44 per share a year ago.
Novavax's quarterly loss shrinks as it ramps down spending on COVID vaccines
Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 vaccines, its only product on the market.
Novavax Stock Is Rising. Revenue Beat Estimates.
Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from Covid-19 vaccines.
Novavax (NVAX) Declines More Than Market: Some Information for Investors
Novavax (NVAX) closed the most recent trading day at $7.92, moving -1.25% from the previous trading session.
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax to Report Q4 Earnings: Here's What You Can Expect
On NVAX's fourth-quarter earnings call, investors will likely focus on updates on its pipeline.
Novavax (NVAX) Outperforms Broader Market: What You Need to Know
In the closing of the recent trading day, Novavax (NVAX) stood at $8.19, denoting a +0.74% change from the preceding trading day.
Novavax (NVAX) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Novavax (NVAX) closed at $8.45, indicating a +0.24% shift from the previous trading day.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day.
Wall Street Analysts Predict an 81.61% Upside in Novavax (NVAX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
